Clinicopathological and prognostic significance of SPARC expression in gastric cancer: A meta‑analysis and bioinformatics analysis

Sun,Jing; Bai,Yang-Kai; Fan,Zhi-Gang

doi:10.3892/ol.2023.13826

Clinicopathological and prognostic significance of SPARC expression in gastric cancer: A meta‑analysis and bioinformatics analysis

Authors:
- Jing Sun
- Yang-Kai Bai
- Zhi-Gang Fan
View Affiliations

Affiliations: Department of Medical Oncology, Affiliated 3201 Hospital of Xi'an Jiaotong University, Hanzhong, Shaanxi 723000, P.R. China, Department of Urology, Hanzhong Central Hospital, Hanzhong, Shaanxi 723000, P.R. China
Published online on: April 20, 2023 https://doi.org/10.3892/ol.2023.13826
Article Number: 240
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Secreted protein acidic and rich in cysteine (SPARC) is a member of the extracellular matrix glycoprotein family that binds to calcium ions. It may bind to a variety of proteins in the extracellular matrix and also compete with cell membrane surface receptors for growth. In the present study, the relationship between SPARC expression in gastric cancer tissues and the clinicopathological characteristics and prognosis of patients with gastric cancer were systematically evaluated. A meta‑analysis and bioinformatics analysis were performed using the PubMed, Chinese National Knowledge Infrastructure, Kaplan‑Meier (KM)‑plotter, The Cancer Genome Atlas (TCGA), Gene Expression Profiling Interactive Analysis (GEPIA), University of ALabama at Birmingham CANcer (UALCAN), Human Protein Atlas (HPA) and Timer databases. SPARC was mainly expressed in tumor mesenchymal cells. The meta‑analysis indicated that SPARC expression was higher in gastric cancer tissues than in normal tissues. SPARC was associated with the degree of differentiation and distant metastasis. K‑M plotter results indicated that high SPARC expression was negatively associated with overall survival, post‑progression survival and progression‑free survival rates of patients. According to the Oncomine, GEPIA, UALCAN and HPA databases, SPARC mRNA and protein expression was upregulated in gastric cancer vs. normal tissues and was negatively associated with poor patient prognosis. In the TCGA database, univariate analysis indicated that lymph node metastasis and distant metastasis were associated with the prognosis of patients with gastric cancer. Cox multifactorial analysis suggested that high SPARC expression, age and distant metastasis were important factors affecting the survival time of patients with gastric cancer. Analysis with the Timer database indicated that SPARC was closely associated with the proportion of 7 immune‑cell infiltrates in gastric cancer. These findings indicated that high expression of SPARC may be a potential marker of tumorigenesis and metastasis in patients with gastric cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zuo TT, Zheng RS, Zeng HM, Zhang SW and Chen WQ: Epidemiology of stomach cancer in China. Chin J Clin Oncol. 44:52–59. 2017.(In Chinese).
3	Han W, Xu XX, He DW, Cao F and Ding HZ: Effect of SPARCL1 gene on the proliferation and apoptosis of hepatocellular carcinoma SMMC-7721 cells. J Jiangsu Univ. 26:52016.(In Chinese).
4	Chun Y, Yamakoshi Y, Kim JW, Iwata T, Hu JCC and Simmer JP: Porcine SPARC: Isolation from dentin, cDNA sequence, and computer model. Eur J Oral Sci. 114:78–85. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS and Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 159:609–622. 2001. View Article : Google Scholar : PubMed/NCBI
6	Rotllant J, Liu D, Yan YL, Postlethwait JH, Westerfield M and Du SJ: Sparc (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear. Matrix Biol. 27:561–572. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ji R, Zhou YN, Ren TW, Zhang ZY and Li Q: Expression and clinical significance of MMP-9 in gastric cancer and metastatic lymphnodes. Chin J Clin Oncol. 37:377–380. 2010.(In Chinese).
8	De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH and Byzova TV: Molecular pathway for cancer metastasis to bone. J Biol Chem. 278:39044–39050. 2003. View Article : Google Scholar : PubMed/NCBI
9	Yang ML, Zhai LL, Ma LH, et al: Expression of SPARC and VEGF in Gastric Carcinoma and Their Relationship with Angiogenesis. J Diag Pathol. 19:52–55. 2012.(In Chinese).
10	Li CY and Gu KS: Expression of CD133, SPARC and ARID1A in gastric cancer and its clinical significance. Chin Clin Oncol. 19:411–416. 2014.(In Chinese). PubMed/NCBI
11	Wang GM, Yuan YP, Zhao CX and Song XL: Expression and significance of MMP-2, MMP-9 and VEGF in colon carcinoma tissues. Chin J Cancer Prevent Treat. 18:1267–1269. 2011.(In Chinese).
12	Nishie A, Masuda K, Otsubo M, Migita T, Tsuneyoshi M, Kohno K, Shuin T, Naito S, Ono M and Kuwano M: High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res. 7:2145–2151. 2001.PubMed/NCBI
13	Thomas R, True LD, Bassuk JA, Lange PH and Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 6:1140–1149. 2000.PubMed/NCBI
14	Wells GA, She B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.aspMay 13–2022
15	Li R: Expression of protein Smad3, HER2, SPARC in gastric cancer tissues and its relation with long-term efficacy. Shanghai Med Pharm J. 35:32014.(In Chinese).
16	Li Y, Wu JF, Zhang H, Qin R and Wang DB: Expression of SPARC in gastric cancer tissues. Acta Universitatis Medicinalis Anhui. 41:626–628. 2006.(In Chinese).
17	Dong MX, Yang YH and Yu JX: Expression of SPARC in gastric carcinoma and clinical significance. Med J Qilu. 26:105–108. 2011.(In Chinese).
18	Ma Y, Zhu J, Chen S, Ma J, Zhang X, Huang S, Hu J, Yue T, Zhang J, Wang P, et al: Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer. Cancer Cell Int. 19:1372019. View Article : Google Scholar : PubMed/NCBI
19	Franke K, Carl-Mcgrath S, Rhl FW, Röhl FW, Lendeckel U, Ebert MP, Tänzer M, Pross M and Röcken C: Differential expression of SPARC in intestinal-type gastric cancer correlates with tumor progression and nodal spread. Transl Oncol. 2:310–320. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wang CS, Lin KH, Chen SL, Chan YF and Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 91:1924–1930. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 16:260–268. 2009. View Article : Google Scholar : PubMed/NCBI
22	Huang HB, Zhao Y and Yang SJ: Research progress of SPARC in esophageal cancer. J Int Oncol. 41:42014.
23	Brekken RA and Sage EH: SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol. 19:816–827. 2001. View Article : Google Scholar : PubMed/NCBI
24	Kupprion C, Motamed K and Sage EH: SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem. 273:29635–29640. 1998. View Article : Google Scholar : PubMed/NCBI
25	Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia. 11:126–135. 2009. View Article : Google Scholar : PubMed/NCBI
26	Feng Y, Yang X and Wang XB: Research advances in secreted protein acidic and rich in cysteine in hepatocellular carcinoma. J Clin Hepatol. 34:419–423. 2018.
27	Ouyang HY, Le Y, Zhang YF, Guo RP and Shi M: Expression of SPARCL1 in primary hepatocellular carcinoma and its clinical significance. Pract J Cancer. 31:32016.
28	Zheng XW, Li WX and Liu JF: Relationship of bcl-2 expression with SPARC expression in hepatocellular carcinoma and their correlation with recurrence, metastasis and prognosis. Chin J Modern Med. 23:42013.(In Chinese).
29	Jiang DL, Cao SQ and Jiang YL: Expression and clinical significance of secreted protein acidic and rich in cysteine and matrix metalloproteinase-2 in human colorectal carcinoma and colorectal adenoma. J Clin Int Med. 34:42017.(In Chinese).
30	Liang JF, Wang HK, Hong X, Li N, Cheng CX, Zhao YZ, Ma YB, Gao JZ, Bai RB and Zheng HX: Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. 29:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nischt R, Wallich M, Reibetanz M, Baumann P, Krieg T and Mauch C: BM-40 and MMP-2 expression are not coregulated in human melanoma cell lines. Cancer Lett. 162:223–230. 2001. View Article : Google Scholar : PubMed/NCBI
32	Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K and Theodorescu D: The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene. 28:3487–3498. 2009. View Article : Google Scholar : PubMed/NCBI
33	Shi S, Ma HY, Han XY, Sang YZ, Yang MY and Zhang ZG: Prognostic significance of SPARC expression in breast cancer: A meta-analysis and bioinformatics analysis. Bio Res Int. 15:86004192022.PubMed/NCBI
34	Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
35	Yin J, Chen G, Liu Y, Liu S, Wang P, Wan Y, Wang X, Zhu J and Gao H: Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J Exp Clin Cancer Res. 29:592010. View Article : Google Scholar : PubMed/NCBI
36	Jie Y, Chen GW, Si L and Liu YC: Effects of SPARC on the invasion ability and MMP-2 expression of gastric cancer cell line HGC27 in vivo. Chin Med Guide. 8:1387–1388. 2010.(In Chinese).
37	Chen ZY, Zhang JL, Yao HX, Wang PY, Zhu J, Wang W, Wang X, Wan YL, Chen SW, Chen GW and Liu YC: Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer. Sci Rep. 4:70352014. View Article : Google Scholar : PubMed/NCBI
38	Liao P, Li W, Liu R, Teer JK, Xu B, Zhang W, Li X, Mcleod HL and He Y: Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer. Onco Targets Ther. 11:6969–6980. 2018. View Article : Google Scholar : PubMed/NCBI
39	Li L, Zhu Z, Zhao Y, Zhang Q, Wu X, Miao B, Cao J and Fei S: FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Sci Rep. 9:78272019. View Article : Google Scholar : PubMed/NCBI
40	Sato T, Oshima T, Yamamoto N, Yamada T, Hasegawa S, Yukawa N, Numata K, Kunisaki C, Tanaka K, Shiozawa M, et al: Clinical significance of SPARC gene expression in patients with gastric cancer. J Surg Oncol. 108:364–368. 2013. View Article : Google Scholar : PubMed/NCBI
41	Wang L, Yang M, Shan L, Qi L, Chai C, Zhou Q, Yao K, Wu H and Sun W: The role of SPARC protein expression in the progress of gastric cancer. Pathol Oncol Res. 18:697–702. 2012. View Article : Google Scholar : PubMed/NCBI